Frontiers in Immunology | |
Immune Conversion of Tumor Microenvironment by Oncolytic Viruses: The Protoparvovirus H-1PV Case Study | |
Laurent Daeffler1  Jean Rommelaere2  Assia Angelova2  Antonio Marchini3  Vitaly I. Pozdeev4  | |
[1] CNRS, UMR7178, Strasbourg, France;Infection, Inflammation and Cancer Program, German Cancer Research Center, Heidelberg, Germany;Laboratory of Oncolytic Virus Immuno-Therapeutics, German Cancer Research Center, Heidelberg, Germany;Laboratory of Oncolytic Virus Immuno-Therapeutics, Luxembourg Institute of Health, Luxembourg, Luxembourg;Université de Strasbourg, IPHC, Strasbourg, France; | |
关键词: oncolytic viruses; H-1PV; immunotherapy; immunogenic cell death; combination therapy; tumor microenvironment; | |
DOI : 10.3389/fimmu.2019.01848 | |
来源: DOAJ |
【 摘 要 】
Cancer cells utilize multiple mechanisms to evade and suppress anticancer immune responses creating a “cold” immunosuppressive tumor microenvironment. Oncolytic virotherapy is emerging as a promising approach to revert tumor immunosuppression and enhance the efficacy of other forms of immunotherapy. Growing evidence indicates that oncolytic viruses (OVs) act in a multimodal fashion, inducing immunogenic cell death and thereby eliciting robust anticancer immune responses. In this review, we summarize information about OV-mediated immune conversion of the tumor microenvironment. As a case study we focus on the rodent protoparvovirus H-1PV and its dual role as an oncolytic and immune modulatory agent. Potential strategies to improve H-1PV anticancer efficacy are also discussed.
【 授权许可】
Unknown